These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8359179)

  • 1. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.
    Young D; Midha KK; Fossler MJ; Hawes EM; Hubbard JW; McKay G; Korchinski ED
    Eur J Clin Pharmacol; 1993; 44(5):433-8. PubMed ID: 8359179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
    Tyndale RF; Kalow W; Inaba T
    Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
    Pan L; Belpaire FM
    Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interconversion between haloperidol and reduced haloperidol in healthy volunteers.
    Chakraborty BS; Hubbard JW; Hawes EM; McKay G; Cooper JK; Gurnsey T; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1989; 37(1):45-8. PubMed ID: 2591462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients.
    Pan L; Vander Stichele R; Rosseel MT; Berlo JA; De Schepper N; Belpaire FM
    Ther Drug Monit; 1999 Oct; 21(5):489-97. PubMed ID: 10519444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?
    Chang WH
    Psychopharmacology (Berl); 1992; 106(3):289-96. PubMed ID: 1570373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
    Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
    Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
    Chang WH; Lin SK; Jann MW; Lam YW; Chen TY; Chen CT; Hu WH; Yeh EK
    Biol Psychiatry; 1989 Jul; 26(3):239-49. PubMed ID: 2742942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs.
    Chang WH; Jaw SS; Wu HS; Tsay L; Yeh EK
    Psychopharmacology (Berl); 1988; 96(3):285-8. PubMed ID: 3146762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
    Chang WH; Lin SK; Jann MW
    J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.
    Fang J; Baker GB; Silverstone PH; Coutts RT
    Cell Mol Neurobiol; 1997 Apr; 17(2):227-33. PubMed ID: 9140699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.
    Someya T; Shimoda K; Suzuki Y; Sato S; Kawashima Y; Hirokane G; Morita S; Yokono A; Takahashi S
    Neuropsychopharmacology; 2003 Aug; 28(8):1501-5. PubMed ID: 12784098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
    Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
    Kudo S; Odomi M
    Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction.
    Someya T; Shibasaki M; Noguchi T; Takahashi S; Inaba T
    J Clin Psychopharmacol; 1992 Jun; 12(3):169-74. PubMed ID: 1629382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.
    Someya T; Takahashi S; Shibasaki M; Inaba T; Cheung SW; Tang SW
    Psychiatry Res; 1990 Feb; 31(2):111-20. PubMed ID: 2326392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients].
    Someya T; Shibasaki M; Takahashi S
    Yakubutsu Seishin Kodo; 1989 Jun; 9(2):207-15. PubMed ID: 2816093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatic ring oxidation of N-n-butylamphetamine is enhanced in the rat by prior treatment with quinidine.
    Coutts RT; Baker GB; Malek F; Hussain MS
    Res Commun Chem Pathol Pharmacol; 1991 Oct; 74(1):15-24. PubMed ID: 1801101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.
    Feifel N; Kucher K; Fuchs L; Jedrychowski M; Schmidt E; Antonin KH; Bieck PR; Gleiter CH
    Eur J Clin Pharmacol; 1993; 45(3):265-9. PubMed ID: 8276052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.